Narrow Results By
CMA's Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
https://policybase.cma.ca/link/policy11125
- Date
- 2014-03-26
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
and abuse of prescription medication
The use of prescription opioid pain relievers is on the rise, in Canada and internationally.
Latest reports indicate that Canada has the second highest per capita consumption of
prescription opioids in the world, after the United States. The misuse and abuse
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847
- Date
- 2016-03-19
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
”.
The CMA has over 83,000 physician-members. Its mission is helping physicians care for
patients and its vision is to be the leader in engaging and serving physicians, and the national
voice for the highest standards for health and health care.
The harms associated with opioids, which include
Harms associated with opioids and other psychoactive prescription drugs
https://policybase.cma.ca/link/policy11535
- Date
- 2015-05-30
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
Service Centre, Canadian Medical Association, 1867 Alta
Vista Drive, Ottawa, ON K1G 5W8; tel 888 855-2555 or 613 731-8610 x2307; fax 613 236-8864.
All polices of the CMA are available electronically through CMA Online (www.cma.ca).
CMA POLICY
HARMS ASSOCIATED WITH OPIOIDS AND OTHER
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017
- Date
- 2018-12-04
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
- Population health, health equity, public health
Policy makers must recognize that prescription opioids are an essential tool in the alleviation of pain and
suffering, particularly in palliative and cancer care.7 Doctors support patients in the management of acute
and chronic pain, as well as problematic substance use, and as such have long been
- Policy Type
- Response to consultation
- Date
- 2018-12-04
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
- Population health, health equity, public health
Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927
- Date
- 2018-08-14
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
-risk in terms of addiction, it is nevertheless an opioid
and should be placed in the Controlled Drugs and Substances Act, under Schedule 1.2
The Canadian Institute for Health Information reports that tramadol is one of six opioids accounting for
96% of all opioid prescriptions between 2012
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921
- Date
- 2018-07-18
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
CMA response:
HEALTH CANADA CONSULTATION
ON RESTRICTION OF MARKETING
AND ADVERTISING OF OPIOIDS
July 18, 2018
The Canadian Medical Association
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health
https://policybase.cma.ca/link/policy11035
- Date
- 2013-11-27
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
for consideration as part of its study on the
government’s role in addressing prescription drug abuse in Canada.
It is increasingly recognized that while prescription medication has an important role in health
care, the misuse and abuse of controlled psychoactive prescription medications, notably
opioids
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734
- Date
- 2017-11-7
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
. Available: https://www.cma.ca/Assets/assets-
library/document/en/advocacy/submissions/hesa-opioid-study-opening-remarks-oct-18-2016-e.pdf (accessed: 2017
Nov 7).
14 Canadian Medical Association. Harms Associated with Opioids and Other Psychoactive Prescription Drugs. CMA
Policy, 2015. Ottawa
Open letter to Ontario Minister of Health about the newly proposed “Consumption and Treatment Services” model
https://policybase.cma.ca/link/policy13932
Proposed amendments to the marihuana for medical purposes regulations
https://policybase.cma.ca/link/policy11293
- Date
- 2014-07-11
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
to
patients and the possibility for misuse or abuse of medications, particularly opioids and other
such substances.
For these reasons, the CMA advocates for an inter-operable, pan-Canadian system of real-time
prescription monitoring and surveillance for controlled substances. Robust monitoring
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations
https://policybase.cma.ca/link/policy11114
- Date
- 2014-03-17
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
of controlled psychoactive prescription medicines, notably opioids
such as oxycodone, fentanyl and hydrocodone, is a significant public health and patient
safety issue. Canada has the second highest per capita consumption of prescription opioids
in the world, after the United States.
The abuse
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936
- Date
- 2016-10-18
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
- Population health, health equity, public health
- Health care and patient safety
crisis related to problematic opioid and fentanyl use.
Physicians are on the front lines in many respects.
Doctors are responsible for supporting patients with the management of acute and chronic
pain. Policy makers must recognize that prescription opioids are an essential tool in the
alleviation
- Policy Type
- Parliamentary submission
- Date
- 2016-10-18
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
- Population health, health equity, public health
- Health care and patient safety
Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931
- Date
- 2018-08-30
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
and other necessary health services; and
• benefit public order by reducing public injecting.3
As you know,Canada is experiencing a large-scale opioid overdose crisis. In Ontario alone,
overdose deaths related to opioids increased by 45 per cent in 2017, with more than three people
dying every day
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295
- Date
- 2014-08-26
- Topics
- Health care and patient safety
- Pharmaceuticals, prescribing, cannabis, drugs
, there was a rise in the use of heroin and other opioids
which did not have abuse deterrent technology
8, 9
.
Tamper-resistant technologies have not been proven to be 100% effective in preventing
abuse. They are not successful in preventing the most common form of abuse, which is the
ingestion of a large